Bellicum Pharmaceuticals (NASDAQ:BLCM) Now Covered by Analysts at

Equities researchers at started coverage on shares of Bellicum Pharmaceuticals (NASDAQ:BLCMGet Rating) in a research note issued to investors on Wednesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, LADENBURG THALM/SH SH downgraded Bellicum Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Wednesday, March 15th.

Bellicum Pharmaceuticals Price Performance

Shares of BLCM opened at $0.80 on Wednesday. Bellicum Pharmaceuticals has a one year low of $0.23 and a one year high of $1.55. The business’s 50 day simple moving average is $0.45 and its 200-day simple moving average is $0.82.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Bellicum Pharmaceuticals stock. HRT Financial LP acquired a new position in shares of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCMGet Rating) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 36,470 shares of the biopharmaceutical company’s stock, valued at approximately $26,000. HRT Financial LP owned approximately 0.42% of Bellicum Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 28.66% of the company’s stock.

About Bellicum Pharmaceuticals

(Get Rating)

Bellicum Pharmaceuticals, Inc is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time.

Further Reading

Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with's FREE daily email newsletter.